Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Molecular Pharmacology

• Publication date

  1997-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/MOL.51.2.301PMID 9203636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ligand binding site of the angiotensin AT1 receptor.

  1996cited by this paper
• 3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists.

  1996cited by this paper
• Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation.

  1996cited by this paper
• L-162,389: a potent orally active angiotensin II receptor antagonist with balanced affinity to both AT1 and AT2 receptor subtypes

  1996cited by this paper
• Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".

  1996cited by this paper
• Non-peptide Angiotensin Agonist

  1995cited by this paper
• Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II.

  1995cited by this paper
• Photoregeneration of bovine rhodopsin from its signaling state.

  1995cited by this paper
• Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subsite by Different Mechanisms (*)

  1995cited by this paper
• Mutagenesis and the Molecular Modeling of the Rat Angiotensin II Receptor (AT1) (*)

  1995cited by this paper
• Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor.

  1995cited by this paper
• The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism (*)

  1995cited by this paper
• Identification of residues involved in ligand binding to the neurokinin-2 receptor.

  1995cited by this paper
• Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor.

  1995cited by this paper
• Mutations in transmembrane segment VIJ of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists

  1994cited by this paper
• Lower efficacy: interaction with an inhibitory receptor or partial agonism?

  1994cited by this paper
• Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan.

  1994cited by this paper
• Identification of peptide binding residues in the extracellular domains of the AT1 receptor.

  1994cited by this paper
• Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor.

  1994cited by this paper
• Pharmacological analysis of drug-receptor interaction: Kenakin, T., 2nd Edn, XII + 483 pp. New York: Raven Press (1993)

  1994cited by this paper
• Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.

  1994cited by this paper
• Locating ligand-binding sites in 7TM receptors by protein engineering.

  1994cited by this paper
• Pharmacologic analysis of drug-receptor interaction

  1994cited by this paper
• Projection structure of rhodopsin

  1993cited by this paper
• Isolation and expression of a novel angiotensin II receptor from Xenopus laevis heart.

  1993cited by this paper
• Toward peptide receptor ligand drugs: progress on nonpeptides.

  1993cited by this paper
• Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.

  1993cited by this paper
• The probable arrangement of the helices in G protein‐coupled receptors.

  1993cited by this paper
• Two different forms of metarhodopsin II: Schiff base deprotonation precedes proton uptake and signaling state.

  1993cited by this paper
• Gene splicing by overlap extension.

  1993cited by this paper
• Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis.

  1992cited by this paper
• Rational design of potent antagonists to the human growth hormone receptor.

  1992cited by this paper
• Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.

  1991cited by this paper
• Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor

  1991cited by this paper
• Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors

  1990cited by this paper
• Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

  1989cited by this paper
• Non-peptide ligands for peptide receptors.

  1989cited by this paper
• Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides.

  1983cited by this paper
• A model of two functionally antagonistic receptor populations activated by the same agonist.

  1977cited by this paper
• Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory.

  1954cited by this paper
• Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory.

  1954cited by this paper

• The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target

  2022cites this paper
• 2-Alkyl substituted benzimidazoles as a new class of selective AT2 receptor ligands.

  2022cites this paper
• Angiotensin II AT2 receptor ligands with phenylthiazole scaffolds.

  2022cites this paper
• High affinity rigidified AT2 receptor ligands with indane scaffolds

  2019cites this paper
• Small‐molecule AT2 receptor agonists

  2018cites this paper
• Synthesis of 11C‐labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [11C]CO

  2016cites this paper
• Tactical Approaches to Interconverting GPCR Agonists and Antagonists.

  2016cites this paper
• Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.

  2016cites this paper
• Multicomponent Reactions in 11 C / 12 C Chemistry – Targeting the Angiotensin II Subtype 2 Receptor

  2016cites this paper
• GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome.

  2015cites this paper
• Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors

  2015cites this paper
• Discovery of Nonpeptide, Selective AT 2 Receptor Agonists

  2015cites this paper
• Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands.

  2015cites this paper
• GPR103 antagonists demonstrating anorexigenic activity in vivo: design and development of pyrrolo[2,3-c]pyridines that mimic the C-terminal Arg-Phe motif of QRFP26.

  2014cites this paper
• Adventures in Medicinal Chemistry

  2014cites this paper
• Sulfur-containing amino acids in 7TMRs: molecular gears for pharmacology and function.

  2013cites this paper
• Comparative Pharmacology of Bombesin Receptor Subtype-3, Nonpeptide Agonist MK-5046, a Universal Peptide Agonist, and Peptide Antagonist Bantag-1 for Human Bombesin Receptors

  2013cites this paper
• Structure of the Human Angiotensin II Type 1 (AT1) Receptor Bound to Angiotensin II from Multiple Chemoselective Photoprobe Contacts Reveals a Unique Peptide Binding Mode*

  2013cites this paper
• Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.

  2013cites this paper
• The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems

  2012cites this paper
• Subtleties in GPCR drug discovery: a medicinal chemistry perspective.

  2012cites this paper
• From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists.

  2012cites this paper
• Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology.

  2011cites this paper
• G-Protein-Dependent and -Independent Signaling Pathways and their Impact on Cardiac Function Compartmentalization of b-Adrenergic Signals in Cardiomyocytes G-Protein-Coupled Receptor Kinases (GRK) as Therapeutic Targets in Cardiovascular Disease Regulators of G-Protein Signaling in the Heart and The

  2011cites this paper
• Biased Ligands for Better Cardiovascular Drugs: Dissecting GPCR Pharmacology G-Protein-Dependent and –Independent Signaling Pathways and their Impact on Cardiac Function Compartmentalization of b-Adrenergic Signals in Cardiomyocytes G-Protein-Coupled Receptor Kinases (GRK) as Therapeutic Targets in

  2011cites this paper
• Dissecting G-Protein-Coupled Receptor Pharmacology

  2011cites this paper
• Non-peptide AT2-receptor agonists.

  2011cites this paper
• Development of selective non-peptide angiotensin II type 2 receptor agonsists

  2010cites this paper
• Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

  2010cites this paper
• Molecular determinants of angiotensin II type 1 receptor functional selectivity.

  2009cites this paper
• Key amino acid residues in the melanocortin-4 receptor for nonpeptide THIQ specific binding and signaling.

  2009cites this paper
• Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships.

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 78 Design , Synthesis and Biological Evaluation of Selective Nonpeptide AT 2 Receptor Agonists and Antagonists

  2008influential citation
• Design, synthesis and biological evaluation of selective nonpeptide AT2 receptor agonists and antagonists.

  2008cites this paper
• Chapter 20 – Substituent Groups

  2008cites this paper
• Angiotensin II increases evoked release at the frog neuromuscular junction through a receptor sensitive to A779.

  2007cites this paper
• The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure.

  2007cites this paper
• Computational approaches on angiotensin receptors and their ligands: recent developments and results.

  2007cites this paper
• Ghrelin Receptor Inverse Agonists: Identification of an Active Peptide Core and Its Interaction Epitopes on the Receptor

  2006cites this paper
• Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.

  2006cites this paper
• Identification of structural determinants for G protein-independent activation of mitogen-activated protein kinases in the seventh transmembrane domain of the angiotensin II type 1 receptor.

  2006cites this paper
• A physicogenetic method to assign ligand-binding relationships between 7TM receptors.

  2005cites this paper
• Recognition of privileged structures by G-protein coupled receptors.

  2004cites this paper
• First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo.

  2004cites this paper
• A non-peptide NK1 receptor agonist showing subpicomolar affinity.

  2004cites this paper
• AT1 Receptor Molecular Aspects

  2004cites this paper
• 29 – DESIGN OF PEPTIDOMIMETICS

  2003cites this paper
• Highly conserved serine in the third transmembrane helix of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor activation.

  2003cites this paper
• Structural determinants for the activation mechanism of the angiotensin II type 1 receptor differ for phosphoinositide hydrolysis and mitogen-activated protein kinase pathways.

  2003cites this paper
• Identification of a series of CCK-2 receptor nonpeptide agonists: Sensitivity to stereochemistry and a receptor point mutation

  2003cites this paper
• Structural Analysis of the Mammalian D2, D3 and D4 Dopamine Receptors

  2003cites this paper
• A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis

  2003cites this paper
• Interaction of a non-peptide agonist with angiotensin II AT1 receptor mutants.

  2002cites this paper
• The First Orally Active Low Molecular Weight Agonists for the LH Receptor: Thienopyr(im)idines with Therapeutic Potential for Ovulation Induction

  2002cites this paper
• Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor.

  2001cites this paper
• Review: Structural requirements for signalling and regulation of AT1-receptors

  2001cites this paper
• Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.

  2001influential citation
• Chimeric AT1/AT2 receptors reveal functional similarities despite key amino acid dissimilarities in the domains mediating agonist-dependent activation.

  2001cites this paper
• Peptide interactions with G-protein coupled receptors.

  2001cites this paper
• Comparative analysis of amphibian and mammalian angiotensin receptors.

  2001cites this paper
• Mutational analysis of the interaction of the N‐ and C‐terminal ends of angiotensin II with the rat AT1A receptor

  2000cites this paper
• The fourth transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle.

  2000cites this paper
• CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.

  2000cites this paper
• Can peptides be mimicked?

  2000cites this paper
• Melanocortins and the brain: from effects via receptors to drug targets.

  2000cites this paper
• Mechanisms of receptor activation and the relationship to receptor structure

  2000cites this paper
• The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.

  2000cites this paper
• Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.

  2000cites this paper
• L-163,491 is a partial angiotensin AT(1) receptor agonist in the hindquarters vascular bed of the cat.

  2000cites this paper
• Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor.

  2000cites this paper
• Nonpeptide mimic of bradykinin with long-acting properties.

  1999cites this paper
• Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997

  1998cites this paper
• Functional interactions of L-162,313 with angiotensin II receptor subtypes and mutants.

  1998cites this paper
• of the Angiotensin II AT 1 Receptor Are Not Involved in Ligand Binding but Participate in Signal Transduction

  1998cites this paper
• Mutagenesis and Modeling of the Neurotensin Receptor NTR1

  1998cites this paper
• Dependence of AT1 angiotensin receptor function on adjacent asparagine residues in the seventh transmembrane helix.

  1998influential citation
• Residues Val254, His256, and Phe259 of the angiotensin II AT1 receptor are not involved in ligand binding but participate in signal transduction.

  1998cites this paper
• Modulation of forskolin‐mediated adenylyl cyclase activation by constitutively active Gs‐coupled receptors

  1997cites this paper
• Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor.

  1997cites this paper
• Chapter 28. Nonpeptide Agonists for Peptide Receptors: Lessons from Ligands

  1997cites this paper